SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

Leading on Studying Short DAPT

Boston Scientific is committed to clinical science that meets what physicians encounter in their everyday practice, including the need for shortened DAPT. We are studying shortened DAPT with the SYNERGY Bioabsorbable Polymer (BP) Stent in various patient populations.

 

SYNERGY BP-DES was intentionally designed to enable short DAPT.

 

 

Hear more from Dr. Aloke Finn talking to Dr. Robert Yeh at
TCT 2019 

Hear more from Dr. Aloke Finn talking to Dr. Robert Yeh at TCT 2019
Video courtesy of TCTMD

SENIOR*

1-month DAPT in stable elderly patients
6-month DAPT in ACS elderly patients
View the SENIOR Trial data  
1,200 Patients
SYNERGY BP-DES vs REBEL™ BMS

EVOLVE Short DAPT

3-month DAPT in HBR patients


View the EVOLVE Short DAPT
Trial data >
 

2,009 Patients
IDE Trial | SYNERGY BP-DES

IDEAL Left Main*

4-month DAPT in Left Main with SYNERGY BP-DES
12-month DAPT in Left Main with Xience™ PP-DES
818 Patients
Left Main PCI

ASET*

0-month DAPT in patients with chronic stable angina

200 Patients
SYNERGY BP-DES

POEM*

1-month DAPT in HBR patients
1,023 Patients
SYNERGY BP-DES

SYNIVUS-DAPT*

1-month DAPT in HBR patients
100 Patients
SYNERGY BP-DES
IVUS
 
Early Healing

Early Healing

Advanced design for optimal healing

Button
Clinical Outcomes

Clinical Outcomes

Outstanding evidence across trials

Button
Efficiency

Efficiency

How design impacts economic value

Button
Top